Home

Securities Fraud Investigation Into Biohaven Ltd. (BHVN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

via Business Wire

The Law Offices of Frank R. Cruz announces an investigation of Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN) on behalf of investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON BIOHAVEN LTD. (BHVN), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.

What Is The Investigation About?

On July 27, 2023, Biohaven disclosed that the FDA had rejected the New Drug Application (“NDA”) for its spinocerebellar ataxia (“SCA”) treatment, troriluzole, having refused to even review the application after the Phase 3 SCA Trial had failed to meet its primary endpoint. On this news, Biohaven’s stock price fell $5.38, or 22.6%, to close at $18.42 per share on July 27, 2023, thereby injuring investors.

Then, on March 3, 2025, Biohaven released its fourth quarter and full year 2024 financial results, disclosing that recent data from a late-stage study of its BHV-7000 treatment for bipolar mania “did not statistically separate from the comparator on the Young Mania Rating Scale primary outcome measure[.]” On this news, Biohaven’s stock price fell $5.12, or 13.8%, to close at $32.06 per share on March 3, 2025.

Then, on April 25, 2025, news reports emerged that, according to the European Medicines Agency (“EMA”), Biohaven had withdrawn its Marketing Authorization Application (“MAA”) for troriluzole in late March 2025. On this news, Biohaven’s stock price fell $3.56, or 15.2%, to close at $19.84 per share on April 25, 2025.

Then, on May 14, 2025, Biohaven announced that “the Division of Neurology 1 within FDA’s Office of Neuroscience informed the Company that they are extending the [Prescription Drug User Fee Act (‘PDUFA’)] date for the troriluzole [NDA] for the treatment of [SCA] by three months to provide time for a full review of Biohaven’s recent submissions related to information requests from the FDA,” and that “[t]he Division also informed Biohaven that it is currently planning to hold an advisory committee meeting to discuss the application, but no date has been scheduled.” On this news, Biohaven’s stock price fell $3.84, or 19.5%, to close at $15.82 per share on May 15, 2025, thereby injuring investors further.

Contact Us To Participate or Learn More:

If you purchased Biohaven securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

The Law Offices of Frank R. Cruz

2121 Avenue of the Stars, Suite 800

Century City, California 90067

Call us at: 310-914-5007

Email us at: info@frankcruzlaw.com

Visit our website at: www.frankcruzlaw.com.

Follow us for updates on Twitter at twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts